The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2023
Filed:
Dec. 01, 2020
Applicants:
Astellas Pharma Inc., Tokyo, JP;
Riken, Saitama, JP;
Inventors:
Ayaka Akiba, Tokyo, JP;
Tatsuya Okudaira, Tokyo, JP;
Yasuhide Masuhara, Tokyo, JP;
Keisuke Ohsumi, Tokyo, JP;
Shinichiro Fujii, Saitama, JP;
Assignees:
RIKEN, Saitama, JP;
ASTELLAS PHARMA INC., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/74 (2006.01); C07K 14/705 (2006.01); C12N 5/10 (2006.01); C12N 5/071 (2010.01); A61K 35/00 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001188 (2018.08); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C07K 14/70539 (2013.01); C12N 5/0686 (2013.01); C12N 5/10 (2013.01); A61K 2039/5156 (2013.01); C12N 2510/00 (2013.01);
Abstract
An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.